SIRT1 and psoriasis: In a phase IIa clinical study on the efficacy of a SIRT1 activator (SRT2104) in psoriasis, 35% patients showed good to excellent histological improvement, but did not demonstrate a dose-dependent response according to histology endpoints [31].